期刊文献+

MRS在儿童后腹膜神经母细胞瘤化疗前后的应用 被引量:1

Study of ^1H-MRS for retroperitoneal neuroblastoma pre- and post-chemotherapy in children
下载PDF
导出
摘要 目的:检测MRS在后腹膜神经母细胞瘤化疗后的MRS频谱变化,研究其在对肿瘤化疗后的组织化学的改变以及对早期治疗的监测作用。材料与方法:20例其化疗前和化疗后或手术前、手术后残留组织化疗分别进行MRI及MRS的检查,男12例,女8例,最小年龄3月,最大年龄12岁,平均4.5岁。MRI扫描仪为GE1.5T机器,线圈为单通道头线圈或体线圈,进行MRI及MRS扫描。1H-MRS是利用单体素多体素混合定位法,将感兴趣区置于肿瘤中央,大小取决于肿瘤的大小。观察肿瘤化疗前后的胆碱峰及活性脂质峰的变化,计算活性脂质峰与胆碱峰比值,用统计学方法比较化疗前后的变化有无统计学意义。结果:恶性肿瘤在化疗前后活性脂质峰与胆碱峰比值变化有统计学意义。结论:儿童后腹膜神经母细胞瘤在化疗后的活性脂质峰与胆碱峰比值有明显的变化,提示可利用1H-MRS来检测脂质与胆碱平衡发生的变化并可作为对化疗敏感性的预测手段。 Objective: To observe the histochemical change of MRS in pre- and post-chemotherapy of retroperitoneal neuroblastoma and predict the resistance or response to chemotherapy by ^1H-MRS. Materials and Methods: MRI and MRS were performed in 20 cases pre- and post-chemotherapy. Twelve were boys and 8 were girls, the age ranged from 3 months to 12 years, the mean age was 4.5. The variation of the ratio of mobile lipid and choline pre- and post-chemotherapy were observed. Results: There is a significant difference of the ratio of mobile lipid and choline pre- and post-chemotherapy. Conclusion: The significant change of the ratio of mobile lipid and choline pre- and post-chemotherapy may be as a tool to predict the resistance or response to chemotherapy.
出处 《中国临床医学影像杂志》 CAS 北大核心 2007年第4期251-253,共3页 Journal of China Clinic Medical Imaging
关键词 儿童 神经母细胞瘤 磁共振成像 child neuroblastoma magnetic resonance imaging
  • 相关文献

参考文献12

  • 1Lee J,Yamaguchi T,Abe A,et al.Clinical evaluation of choline measurement by proton MR spectroscopy in patients with malignant tumors[J].Radiat Med,2004,22:148-154.
  • 2Vaidya SJ,Payne GS,Leach MO.Potential role of magnetic resonance spectroscopy in assessment of tumor response in childhood cancer[J].Eur J Cancer,2003,39:728-735.
  • 3Bezabeh T,Odlum O,Nason R.Prediction of treatment response in head and neck cancer by magnetic resonance spectroscopy[J].AJNR,2005,26:2108-2113.
  • 4Schmitz JE,Kettunen MI,Hu DE.1H MRS-visible lipids accumulate during apoptosis of lymphoma cells in vitro and in vivo[J].Magn Reson Med,2005,54:43-50.
  • 5Hakumaki J,Brindle K.Techniques:visualizing apoptosis using nuclear magnetic resonance[J].Trends Pharmacol Sci,2003,24:146-149.
  • 6Schilling A,Gewiese B,Berger G,et al.Liver tumors:follow-up with P-31 MR spectroscopy after local chemo-therapy and chemoembolization[J].Radiology,1992,82:887-890.
  • 7Lindskog M,Spenger C,Klason T.Proton magnetic resonance spectroscopy in neuroblastoma:current status,prospects and limitations[J].Cancer Lett,2005,228:247-255.
  • 8Lindskog M,Kogner P,Ponthan F.Noninvasive estimation of tumor viability in a xenograft model of human neuroblastoma with proton magnetic resonance spectroscopy (^1H MRS)[J].Br J Cancer,2003,88:478-485.
  • 9Lindskog M,Spenger C,Jarvet J,et al.Predicting resistance or response to chemotherapy by proton magnetic resonance spectroscopy in neuroblastoma[J].J Natl Cancer Inst,2004,96:1457-1466.
  • 10Kaplan O,Kushnir T,Askenazy N,et al.Role of nuclear magnetic resonance spectroscopy (MRS) in cancer diagnosis and treatment:31P,23N,and 1H MRS studies of thress models of pancreatic cancer[J].Cancer Research,1997,57:1452-1459.

同被引文献5

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部